Abstract
Nicotinic α7 receptors have been shown in a variety of studies with animal models to play important roles in diverse components of cognitive function, including learning, memory and attention. Mice with α7 receptor knockouts show impairments in memory. Selective α7 agonists significantly improve learning, memory and attention. α7 receptors in limbic structures such as the hippocampus and amygdala have been demonstrated to play critical roles in memory. Blockade of α7 receptors in these areas cause memory impairments. In the brains of people with schizophrenia α7 receptors are impaired. This may be related to pronounced cognitive impairments seen with schizophrenia. There has been a major effort to develop α7 nicotinic agonists for helping to reverse cognitive impairment. These receptors are a promising target for development of therapeutic treatments for a variety of diseases of cognitive impairment including Alzheimer’s disease, attention deficit hyperactivity disorder (ADHD) and schizophrenia.
Keywords: α7-Nicotinic Receptors, memory, learning, attention, cognition, α7 agonist, deficit models, ADHD, Alzheimer's disease, Schizophrenia
Current Drug Targets
Title:α7-Nicotinic Receptors and Cognition
Volume: 13 Issue: 5
Author(s): Edward D. Levin
Affiliation:
Keywords: α7-Nicotinic Receptors, memory, learning, attention, cognition, α7 agonist, deficit models, ADHD, Alzheimer's disease, Schizophrenia
Abstract: Nicotinic α7 receptors have been shown in a variety of studies with animal models to play important roles in diverse components of cognitive function, including learning, memory and attention. Mice with α7 receptor knockouts show impairments in memory. Selective α7 agonists significantly improve learning, memory and attention. α7 receptors in limbic structures such as the hippocampus and amygdala have been demonstrated to play critical roles in memory. Blockade of α7 receptors in these areas cause memory impairments. In the brains of people with schizophrenia α7 receptors are impaired. This may be related to pronounced cognitive impairments seen with schizophrenia. There has been a major effort to develop α7 nicotinic agonists for helping to reverse cognitive impairment. These receptors are a promising target for development of therapeutic treatments for a variety of diseases of cognitive impairment including Alzheimer’s disease, attention deficit hyperactivity disorder (ADHD) and schizophrenia.
Export Options
About this article
Cite this article as:
Edward D. Levin , α7-Nicotinic Receptors and Cognition , Current Drug Targets 2012; 13 (5) . https://dx.doi.org/10.2174/138945012800398937
DOI https://dx.doi.org/10.2174/138945012800398937 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Purine Ionotropic (P2X) Receptors
Current Pharmaceutical Design Transcranial Direct Current Stimulation - An Adjuvant Tool for the Treatment of Neuropsychiatric Diseases?
Current Psychiatry Reviews Editorial [Hot Topic: The Pineal Hormone Melatonin in Health and Disease (Guest Editors: Charanjit Kaur)]
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Adult Stem Cell Application in Spinal Cord Injury
Current Drug Targets Maternal Sodium Valproate Exposure Alters Neuroendocrine-Cytokines and Oxido-inflammatory Axes in Neonatal Albino Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets In Silico Dynamic Molecular Interaction Networks for the Discovery of New Therapeutic Targets
Current Pharmaceutical Design Neuroprotection by Natural Polyphenols: Molecular Mechanisms
Central Nervous System Agents in Medicinal Chemistry Autoimmune Channelopathies of the Nervous System
Current Neuropharmacology Microglial Activation as a Compelling Target for Treating Acute Traumatic Brain Injury
Current Medicinal Chemistry Codon Usage Biases in Alzheimers Disease and Other Neurodegenerative Diseases
Protein & Peptide Letters Neurotoxicity and Side-Effects of Highly Active Antiretroviral Therapy [HAART] on the Central and Peripheral Nerve System
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Insulin Growth Factor-I Promotes Functional Recovery After a Focal Lesion in the Dentate Gyrus
CNS & Neurological Disorders - Drug Targets EEG Correlates of Cognitive Functions and Neuropsychiatric Disorders: A Review of Oscillatory Activity and Neural Synchrony Abnormalities
Current Psychiatry Research and Reviews The Serpin Solution; Targeting Thrombotic and Thrombolytic Serine Proteases in Inflammation
Cardiovascular & Hematological Disorders-Drug Targets CB1 Cannabinoid Receptors and their Associated Proteins
Current Medicinal Chemistry Melatonin Effects in REM Sleep Behavior Disorder Associated with Obstructive Sleep Apnea Syndrome: A Case Series
Current Alzheimer Research The Role of Structure Activity Relationship Studies in the Search for New GABA Uptake Inhibitors
Mini-Reviews in Medicinal Chemistry GABA Transporters and GABA-Transaminase as Drug Targets
Current Drug Targets - CNS & Neurological Disorders In-vitro Functionality of Clozapine Biphasic Release Minitablet Using Advanced Statistical Tools
Drug Delivery Letters Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets